🔥 📰 LATEST GLP-1 NEWS! [keto gummy bears uk]

🔥 📰 LATEST GLP-1 NEWS! [keto gummy bears uk]

| 1h 28m 28s | Video has closed captioning.

Novo Nordisk Advertising: Novo Nordisk launches new advertising campaign "The Power of Wegovy" This advertisement includes the new indication for reduction of cardiovascular risk For 2023, the #5 advertising spend for a drug was Rybelsus at $191 million. The #6 advertising spend was Ozempic at $187.4 million (increase of 6% from 2022). More than 40% of the 2023 ad spend for Ozempic went to online video platforms (i.e. social media like youtube) Link: Structure Therapeutics GSBR-1290 GSBR-1290 is a small molecule GLP-1 pill In a 12-week phase 2 clinical study, a tablet formulation of GSBR-1290 had a weight-loss of 6.9%. This is comparable to Eli Lilly's phase 2 results for olforglipron At Week 12, 67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% achieved ≥ 10% weight loss, compared to 0% for placebo Also developing next generation combination GLP-1 candidates together with GIP, amylin, glucagon and apelin oral small molecules Link (Madison Muller): Elon musk tweet: Elon Musk tweeted: Just make a lot of Ozempic/Mounjaro. It’s not inherently expensive. The health benefits of reducing obesity far exceed the downside of GLP-1 inhibitors. We evolved under starving conditions and now make food that is plentiful and delicious. Whether that food is “processed” does matter, but is not a game changer This tweet has currently been seen 325,500 times Shanghai Stem Cell Type 2 Diabetes Treatment